14 results match your criteria: "Shangqiu Municipal Hospital[Affiliation]"

Azvudine and nirmatrelvir-ritonavir (Paxlovid) were widely used to treat patients with COVID-19 in China during the Omicron wave. However, the efficacy and safety of azvudine versus Paxlovid are poorly established. This study included 40,876 hospitalized patients with COVID-19 from eleven hospitals in Henan and Xinjiang Provinces, China.

View Article and Find Full Text PDF

Real-world effectiveness and safety of azvudine in hospitalized patients with SARS-CoV-2 infection: A multicenter, retrospective cohort study.

J Infect

December 2024

Department of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. Electronic address:

Objectives: Azvudine has been designated as a priority treatment for patients infected with SARS-CoV-2, however, clinical evidence in hospitalized cases remains insufficient.

Methods: We performed a multi-center, retrospective cohort study to evaluate the effectiveness and safety of azvudine in hospitalized patients with SARS-CoV-2 in China (NCT06349655). Kaplan-Meier method, Cox regression model, subgroup analysis, and seven sensitive analyses were employed.

View Article and Find Full Text PDF
Article Synopsis
  • A phase III trial involving 12 centers in China compared the effectiveness of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with apatinib against DEB-TACE alone for patients with unresectable hepatocellular carcinoma (uHCC).
  • The results showed that the combination treatment led to significantly better progression-free survival (7.1 months vs. 5.2 months) and overall survival (23.3 months vs. 18.9 months), along with higher response rates and disease control.
  • Most treatment-related adverse events were mild, although there were some increased risks of side effects such as hypertension and fatigue associated with the combination therapy, which still had an overall favorable safety profile
View Article and Find Full Text PDF

Synthesis and clinical application of new drugs approved by FDA in 2023.

Eur J Med Chem

February 2024

Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University, College of Pharmacy, Yanji, Jilin, 133002, China; Rega Institute for Medical Research, Medicinal Chemistry, KU Leuven, Herestraat 49-Box 1041, 3000, Leuven, Belgium. Electronic address:

In 2023, the U.S. Food and Drug Administration (FDA) granted approval to a total of 55 new drugs, comprising 29 new chemical entities (NCEs) and 25 new biological entities (NBEs).

View Article and Find Full Text PDF

Background: Circular RNAs (circRNAs) play important roles in the occurrence and development of cancer and chemoresistance. DNA damage repair contributes to the proliferation of cancer cells and resistance to chemotherapy-induced apoptosis. However, the role of circRNAs in the regulation of DNA damage repair needs clarification.

View Article and Find Full Text PDF

Background: The evidence of transcatheter arterial chemoembolization (TACE) plus tyrosine kinase inhibitor and immune checkpoint inhibitor in unresectable hepatocellular carcinoma (HCC) was limited. This study aimed to evaluate the role of TACE plus apatinib (TACE + A) and TACE combined with apatinib plus camrelizumab (TACE + AC) in patients with unresectable HCC.

Methods: This study retrospectively reviewed patients with unresectable HCC who received TACE + A or TACE + AC in 20 centers of China from January 1, 2019 to June 31, 2021.

View Article and Find Full Text PDF

Coronavirus disease 2019 (COVID-19) remains an uncontained, worldwide pandemic. While battling the disease in China, the Chinese government has actively promoted the use of traditional Chinese medicine, and many studies have been conducted to determine the efficacy of traditional Chinese medicine for treating COVID-19. The present review discusses the effectiveness and safety of traditional Chinese medicine in curing COVID-19 and provides clinical evidence from all confirmed cases in China.

View Article and Find Full Text PDF

Using a cross-sectional study, 246 patients with hemorrhage and transformation after cerebral ischemic stroke(CIS) thrombolysis who were admitted to Shangqiu First People's Hospital, Shangqiu Municipal Hospital, and Shangqiu Liangyuan Traditional Chinese Medicine Hospital from March 2018 to May 2020 were selected as the observation group, 246 patients with no hemorrhage transformation after CIS thrombolysis during the same period were selected as the control group with a ratio of 1∶1. Polymerase chain reaction and pyrosequencing methods were used to detect the single nucleotide polymorphisms of the two groups of 1 genes. The frequency distribution of each genotype of the two groups of 1 gene polymorphism sites was counted.

View Article and Find Full Text PDF

Absent in melanoma 1-like (AIM1L) serves as a novel candidate for overall survival in hepatocellular carcinoma.

Bioengineered

December 2021

Department of Integrative Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.

Identifying biomarkers for hepatocellular carcinoma (HCC) survival is of great importance for the early detection, monitoring, and predicting for prognosis. This study aimed to investigate the candidate biomarkers for predicting overall survival (OS) in HCC patients. Using RTCGAToolbox, top 50 upregulated differential expressed genes (DEGs) were identified.

View Article and Find Full Text PDF

Generation of a human iPSC line CIBi009-A from a patient with familial hypercholesterolemia carrying variants of LDLR c.T1241G and APOB c.G1618T.

Stem Cell Res

May 2021

Cell Inspire Biotechnology Co., Ltd., Shenzhen 518101, China; Cell Inspire Therapeutics Co., Ltd., Shenzhen 518101, China. Electronic address:

Patients with familial hypercholesterolemia (FH) are susceptible to premature coronary artery disease. We generated a human iPSC line CIBi009-A from a patient with FH who carried variants of LDLR c.T1241G and APOB c.

View Article and Find Full Text PDF

This cohort study examines the clinical characteristics of men with coronavirus disease 2019 whose semen tested positive for severe acute respiratory syndrome coronavirus 2.

View Article and Find Full Text PDF

Recurrent PCR positivity after hospital discharge of people with coronavirus disease 2019 (COVID-19).

J Infect

July 2020

Deparment of Infection The People's Hopspital of Suzhou New District, No. 95 Huashan Road, Suzhou High-tech zone, Suzhou, 215129, China; Department of Infection Diseases, The People's Hospital of Suzhou New District, Suzhou, Jiangsu 215129, China. Electronic address:

View Article and Find Full Text PDF